Richard Menziuso
VP, Global Controller & Principal Accounting OfficerMr. Richard Menziuso is Vice President, Global Controller and Principal Accounting Officer of Altimmune, Inc. from September 29, 2026. Mr. Menziuso has finance and accounting experience, including 12 years in public accounting. Prior to joining the Company, Mr. Menziuso served as Vice President, Corporate Controller of Centessa Pharmaceuticals plc, a biopharmaceutical company, from 2021 until its 2026 acquisition by Eli Lilly. Prior to joining Centessa, Mr. Menziuso served as North America Controller and Head of Global Finance Customer Solutions at Thermo Fisher Scientific (NYSE: TMO) from 2019 to 2021 and as Vice President, Accounting and Controller at Axovant Gene Therapies (Nasdaq: formerly AXGT, now SIOX) from 2017 to 2019. Earlier in his career, Mr. Menziuso held finance and accounting roles at LifeCell Corporation, ConvaTec Healthcare, Tyco International, PricewaterhouseCoopers and Bristol-Myers Squibb. Mr. Menziuso received a B.B.A. in Public Accounting from Pace University and is a Certified Public Accountant and Chartered Global Management Accountant.
Positions
- Company NameAltimmune, Inc.Stock CodeALTPositionVP, Global Controller & Principal Accounting OfficerColleagues
- JBJerome Benedict DursoChairman, CEO & President
- MSM. Scot RobertsChief Scientific Officer
- CAChristophe Arbet-EngelsChief Medical Officer
- GLGregory L. WeaverChief Financial Officer
- PLPhilip L. HodgesIndependent Director
- WFWayne F. PisanoIndependent Director
- CACatherine Angell SohnIndependent Director
- KOKlaus O. SchaferIndependent Director
